Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials.
about
Ribavirin monotherapy for chronic hepatitis CRibavirin plus interferon versus interferon for chronic hepatitis CAntiviral therapy for chronic hepatitis C in patients with human immunodeficiency virusDoes anybody read "evidence-based" articles?Managing Occupational Risks for Hepatitis C Transmission in the Health Care SettingEfficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A virusesMedicinal herbs for hepatitis C virus infection: a Cochrane hepatobiliary systematic review of randomized trials.Evolution of interferon-based therapy for chronic hepatitis C.Treatment of chronic hepatitis C: a systematic review.Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection.Hepatitis infection in the treatment of opioid dependence and abuse.Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health anAntiviral combination therapy with interferon/peginterferon plus ribavirin for patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Agency for Health Technology Assessment.Managing pediatric hepatitis C: current and emerging treatment options.A randomized trial of 24 versus 48 weeks of peginterferon α-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: a multicenter national study in Japan.IL28B SNP rs12979860 is the Critical Predictor for Sustained Viral Response in Chinese Children Aged 1 to 6 Years with Chronic Hepatitis C.Peginterferon plus ribavirin for chronic hepatitis C in patients with human immunodeficiency virus.Antiviral therapy for hepatitis C: why are so few patients being treated?Hepato-biliary clinical trials and their inclusion in the Cochrane Hepato-Biliary Group register and reviews.Cell-type and donor-specific transcriptional responses to interferon-alpha. Use of customized gene arrays.Public health impact of antiviral therapy for hepatitis C in the United States.Randomized trial of low-dose peginterferon α-2b plus low and escalating doses of ribavirin in older patients with chronic hepatitis C with high viral load genotype 1.Randomized trial of peginterferon alpha-2b plus low and escalating dose of ribavirin in patients with chronic hepatitis C with high viral load genotype 1.Lack of a strong association between HLA class II, tumour necrosis factor and transporter associated with antigen processing gene polymorphisms and virological response to alpha-interferon treatment in patients with chronic hepatitis C.Efficacy of short-term interferon therapy for patients infected with hepatitis C virus genotype 2a.A randomized trial to assess the efficacy of interferon-alpha daily in combination with ribavirin in the treatment of naïve patients with chronic hepatitis C.A randomized trial to assess the efficacy of interferon alpha in combination with ribavirin in the treatment of interferon alpha nonresponders with chronic hepatitis C: superior efficacy of high daily dosage of interferon alpha in genotype 1.Ribavirin, but not interferon alpha-2b, is associated with impaired osteoblast proliferation and differentiation in vitro.Current antiviral combination therapy for chronic hepatitis C patients who failed to interferon alfa-based treatment.[The sustained response rates for chronic hepatitis C patients undergoing therapy with the several interferons and ribavarins supplied by Brazilians Health Ministry is comparable to those reported in the literature].Hepatitis C (chronic)Combination Therapy of Interferon and Ribavirin Versus Interferon Monotherapy in Treatment of Chronic Hepatitis C: A Meta-analysis of Clinical TrialsFunding, disease area, and internal validity of hepatobiliary randomized clinical trials
P2860
Q24240057-E4B46631-D39B-4056-93F2-255AB9B28F86Q24240879-8DDDC78F-90F2-419B-9D36-B1ED3A246DD0Q24246928-9A72D7DE-DC68-40A5-BF6D-0F245A7A2A98Q24795056-B16CE72F-3DB8-4ABF-8A33-7164E5EB93AEQ27477626-E5766557-F372-4CB4-A97D-E00D76D99B9DQ28479036-44046BFC-A815-413D-A385-92A300A458F2Q33965076-E6863A46-B761-4927-BDC9-8B9DCE69F833Q34342092-017BAF9F-CF78-4503-AB3E-71AF079600DEQ34984085-537B8E26-D7B3-449A-A465-5C9C0231ED54Q35205389-198105AB-821A-4635-A124-DE229A9D5D09Q35389163-691B6490-2C5D-47A7-AB90-28FAA9463ADCQ36057039-A63D092D-61E9-444D-ACD4-DA9BC35CEFAFQ37244056-5F07ABBA-7DDE-47AE-8D26-C2F8CA51CF62Q37316248-90BB67B3-D893-463A-8261-9F1385803E9AQ37356788-7EC613CD-9C93-4D44-AB2C-6F7F09026862Q37428173-11C6BDF2-31DD-4A1A-B56A-DA7A081993ABQ37513556-3A49C2BB-A081-4606-9E10-0B81DEA52783Q37749115-13133F9E-79BC-4E6A-9E3F-335484796EAAQ37854837-2C27E0D7-7118-443C-8EC7-C82290E7FCB2Q38361837-8BBF37B8-02B5-45AF-89EA-3D57A331A125Q39939298-65C099BA-DE6B-4484-8B95-8AA54D81B636Q40902801-487F4E15-434B-4A5E-B692-A2C7FCFF4EA5Q41528192-35548959-A26C-4AC7-9167-7AC78E8902F7Q42988918-5CDF97C8-3721-43F7-A1EA-3FD2EC20E841Q42991438-C0F10C63-9AA7-4CFB-8DAB-5DAF4423E2EFQ43046523-55E7D770-0941-42B2-AC15-162906B42AA4Q43048560-4C0762C8-6770-424E-A0B1-4EECF615D3B3Q44899913-BCB9E90F-8C86-4969-A981-1019B5B84870Q50550986-E5AF3893-F7BF-4057-9892-445E11067DB2Q50580363-625D7664-78F4-46E1-AF6B-5A7BC95F96EAQ56932766-717EA589-F45E-48C4-9A45-C45A8F25CC4CQ57312199-DE6F15F9-7358-4B8A-BDF9-848340EADD0EQ57389775-F79730AA-FD28-404D-8F24-51213332E285
P2860
Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials.
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Interferon alfa with or withou ...... c review of randomised trials.
@ast
Interferon alfa with or withou ...... c review of randomised trials.
@en
type
label
Interferon alfa with or withou ...... c review of randomised trials.
@ast
Interferon alfa with or withou ...... c review of randomised trials.
@en
prefLabel
Interferon alfa with or withou ...... c review of randomised trials.
@ast
Interferon alfa with or withou ...... c review of randomised trials.
@en
P2860
P1433
P1476
Interferon alfa with or withou ...... c review of randomised trials.
@en
P2093
L L Kjaergard
P2860
P304
P356
10.1136/BMJ.323.7322.1151
P407
P577
2001-11-01T00:00:00Z